Table 1: Input for cost-benefit analysis.
| Variables category | Variable name | Distribution* | Value (base case) | Relative change (range) | Reference |
|---|---|---|---|---|---|
| Drug costs of apixaban per year | cRiva | triangular | €1253.74 | (± 20%) €1002.99-€1504.49 | Red List [Rote Liste®] 2019 |
| Drug costs of dabigatran per year | cDabi | triangular | €1197.77 | (± 20%) (€958.21 - €1437.32) | Red List [Rote Liste®] 2019 |
| Drug costs of edoxaban per year | cEdox | triangular | €1099.48 | (± 20%) €870.79-€1306.18 | Red List [Rote Liste®] 2019 |
| Drug costs of rivaroxaban per year | cRiva | triangular | €1194.59 | (± 20%) €955.67- €1433.51 | Red List [Rote Liste®] 2019 |
| Costs of phenprocoumon per year | cMarcu | triangular | €66.78 | (± 20%) €53.42-€80.14 | Red List [Rote Liste®] 2019 |
| Costs of hemorrhagic stroke per event | cHStroke | uniform | €5480.52 | (± 20%) €4384.42-€6576.62 | calculated |
| Costs of ischemic stroke per event | cIStroke | uniform | €4948.78 | (± 20%) €3595.02-€5938.54 | calculated |
| Costs of major bleeding per event | cMajorBL | uniform | €3814.39 | (± 20%) €3051.51-€4577.27 | calculated |
| Costs of care by settled physician per year | cPausch | uniform | €113.40 | (± 20%) €90.72-€136.08 | EBM [19] |
| Costs of laboratory controls by physician for self-managing patients per year | cCoalab | triangular | €3.6 | (± 20%) €2.88-€4.32 | EBM [19] |
| Costs of training when using Coaguchek | cCoatrain | uniform | €166.64 | (± 20%) €84-€150 | Own interviews |
| Costs of one CoaguChek test strip | cCoastrip | uniform | €2.86 | (± 20%) €2.288-€3.43 | Internet best price |
| Costs of CoaguChek INR device | cCoasyst | uniform | €671.35 | (± 20%) €537.08-€805.62 | Internet best price |
| Period of depreciation | pDepr | triangular | 5 yr | 3-10 yr | German depreciation guidelines |
| TTR difference between approval study and 78% | DELTA_Apix | - | 0.16 | - | calculated |
| TTR difference between approval study and 78% | DELTA_Dabi | - | 0.14 | - | calculated |
| TTR difference between approval study and 78% | DELTA_Edox | - | 0.13 | - | calculated |
| TTR difference between approval study and 78% | DELTA_Riva | - | 0.23 | - | calculated |
| No. of hemorrhagic strokes per patient at risk and year under apixaban | noHS_Apix | uniform | 0.0024 | (95% CI) 0.0014-0.0034 | [3] |
| No. of hemorrhagic strokes per patient at risk and year under dabigatran | noHS_Dabi | uniform | 0.0010 | (95% CI) 0.0002-0.0018 | [4] |
| No. of hemorrhagic strokes per patient at risk and year under edoxaban | noHS_Edox | uniform | 0.0026 | (95% CI) 0.0014-0.0038 | [7] |
| No. of hemorrhagic strokes per patient at risk and year under rivaroxaban | noHS_Riva | uniform | 0.0026 | (95% CI) 0.0013-0.0039 | [5,6] |
| No. of hemorrhagic strokes per warfarin patient at risk and year in the apibaxan trial | noHS_War_Apix | uniform | 0.0047 | (95% CI) 0.0033-0.0061 | [3] |
| No. of hemorrhagic strokes per warfarin patient at risk and year in the dabigatran trial | noHS_War_Dabi | uniform | 0.0038 | (95% CI) 0.0022-0.0054 | [4] |
| No. of hemorrhagic strokes per warfarin patient at risk and year in the edoxaban trial | noHS_War_Edox | uniform | 0.0047 | (95% CI) 0.0031-0.0063 | {7] |
| No. of hemorrhagic strokes per warfarin patient at risk and year in the rivaroxaban trial | noHS_War_Riva | uniform | 0.0042 | (95% CI) 0.0025-0.0059 | [5,6] |
| No. of ischemic strokes per patient at risk and year under apixaban | noIS_Apix | uniform | 0.0097 | (95% CI) 0.0077-0.0177 | [3] |
| No. of ischemic strokes per patient at risk and year under dabigatran | noIS_Dabi | uniform | 0.0092 | (95% CI) 0.0068-0.0116 | [4] |
| No. of ischemic strokes per patient at risk and year under edoxaban | noIS_Edox | uniform | 0.0125 | (95% CI) 0.0092-0.0148 | [7] |
| No. of ischemic strokes per patient at risk and year under rivaroxaban | noIS_Riva | uniform | 0.012 | (95% CI) 0.0092-0.0148 | [5,6] |
| No. of ischemic strokes per warfarin patients at risk and year in the apixaban trial | noIS_War_Apix | uniform | 0.0105 | (95% CI) 0.0148-0.0126 | [3] |
| No. of ischemic strokes per warfarin patient at risk and year in the dabigatran trial | noIS_War_Dabi | uniform | 0.012 | (95% CI) 0.0092-0.0148 | [4] |
| No. of ischemic strokes per wafarin patient at risk and year under edoxaban | noIS_War_Edox | uniform | 0.0125 | (95% CI) 0.0099-0.0151 | [7] |
| No. of ischemic strokes per warfarin patient at risk and year in the rivaroxaban trial | noIS_War_Riva | uniform | 0.0134 | (95% CI) 0.0104-0.0164 | [5,6] |
| No. of major bleedings per patient at risk and year under apixaban | noMajorBL_Apix | uniform | 0.0407 | (95% CI) 0.0366-0.0488 | [3] |
| No. of major bleedings per patient at risk and year under dabigatran | noMajorBL_Dabi | uniform | 0.0311 | (95% CI) 0.0267-0.0355 | [4] |
| No. of major bleedings per patient at risk and year under edoxaban | noMajorBL_Edox | uniform | 0.0275 | (95% CI) 0.0237-0.0313 | [7] |
| No. of major bleedings per patient at risk and year under rivaroxaban | noMajorBL_Riva | uniform | 0.0339 | (95% CI) 0.0292-0.0386 | [5,6] |
| No. of cases of major bleedings per warfarin patient at risk and year in the apibaxan trial | noMajorBL_War_Apix | uniform | 0.0601 | (95% CI) 0.0552-0.065 | [3] |
| Number of major bleedings per warfarin patient at risk and year in the dabigatran trial | noMajorBL_War_Dabi | uniform | 0.0336 | (95% CI) 0.029-0.0382 | [4] |
| Number of cases of major bleedings per warfarin patient at risk and year in the edoxaban trial | noMajorBL_War_Edox | uniform | 0.0343 | (95% CI) 0.03-0.0313 | [7] |
| No. of cases of major bleedings per warfarin patient at risk and year in the rivaroxaban trial | noMajorBL_War_Riva | uniform | 0.0317 | (95% CI) 0.271-0.0363 | [5,6] |
*in probabilistic sensitivity analysis